Structural dynamics underlying rho1 GABAC receptor activation and antagonism

rho1 GABAC 受体激活和拮抗作用的结构动力学

基本信息

项目摘要

DESCRIPTION (provided by applicant): 3-aminobutyric acid (GABA)-gated chloride channels (GABAA and GABAC receptors) play important roles in fast synaptic inhibition in the mammalian brain. They are also the major targets of many clinically useful neuroactive compounds. Dysfunction of these GABA-gated ion channels can result in epilepsy and other neural disorders. Binding of GABA to its receptor is thought to initiate a conformational wave starting from the binding site(s) and propagating to the gating machinery to open the pore. Gaining insights into the dynamic structural basis of these conformational rearrangements therefore is the key step to understanding the mechanism of GABA receptor activation and antagonism. However, despite intensive structure-function relationship studies in the past, structural dynamics underlying GABA receptor activation is still not fully understood. This project seeks to provide new insights into structural bases for GABAC receptor function by employing techniques successfully adapted in this laboratory. The first aim is to use site-specific fluorescence combined with substituted cysteine accessibility analysis and electrophysiological recording to define agonist-induced structural rearrangements in the subunit interface underlying channel activation. The second aim is to use fluorescence resonance energy transfer (FRET) to detect conformational changes not located in subunit interface and to deduce their moving direction during receptor activation. The third aim is to use site-specific fluorescence and FRET to define agonist-induced movements antagonizable by noncompetitive antagonists. The fourth aim is to validate the functional significance of the moving residues identified by previous aims by single channel analysis and explore coupling mechanism by mutant cycle analysis. Collectively, this work will allow us to detect conformational changes in and out of subunit interface underlying GABA receptor activation and antagonism. These studies will test the project's central hypothesis that GABA receptor activation involves an agonist-induced rotation of the N-terminal domain, which then propagates to the gating machinery to open the pore. Insights gained from this work will illuminate mechanisms of receptor activation and antagonism that have potential applicability more generally to the entire class of ligand-gated ion channels. The findings also will provide a structural basis for development of new therapeutics or research tools targeting GABA receptors.
描述(申请人提供):3-氨基丁酸(GABA)门控氯通道(GABAA和GABAC受体)在哺乳动物大脑中的快速突触抑制中发挥重要作用。它们也是许多临床上有用的神经活性化合物的主要靶点。这些GABA门控离子通道的功能障碍可能会导致癫痫和其他神经疾病。GABA与其受体的结合被认为是从结合部位(S)开始启动构象波,并传播到门控机械以打开气孔。因此,深入了解这些构象重排的动态结构基础是理解GABA受体激活和拮抗机制的关键一步。然而,尽管过去对结构-功能关系进行了深入的研究,但GABA受体激活背后的结构动力学仍然不完全清楚。该项目试图通过采用本实验室成功采用的技术,为GABAC受体功能的结构基础提供新的见解。第一个目标是使用位点特异性荧光结合取代半胱氨酸可及性分析和电生理记录来确定激动剂诱导的通道激活亚基界面上的结构重排。第二个目的是利用荧光共振能量转移(FRET)检测受体激活过程中不在亚基界面的构象变化,并推测其运动方向。第三个目标是使用特定部位的荧光和FRET来定义激动剂诱导的运动可被非竞争性拮抗剂拮抗。第四个目的是通过单通道分析来验证先前目标确定的移动残基的功能意义,并通过突变循环分析来探索偶联机制。总而言之,这项工作将使我们能够检测在GABA受体激活和拮抗基础上的亚单位界面内外的构象变化。这些研究将检验该项目的中心假设,即GABA受体的激活涉及激动剂诱导的N-末端结构域的旋转,然后该结构域传播到门控机械以打开气孔。从这项工作中获得的见解将阐明受体激活和拮抗的机制,这些机制具有更广泛的潜在适用性,适用于整个类别的配体门控离子通道。这些发现还将为开发针对GABA受体的新疗法或研究工具提供结构基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yongchang Chang其他文献

Yongchang Chang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yongchang Chang', 18)}}的其他基金

Structural dynamics underlying rho1 GABAC receptor activation and antagonism
rho1 GABAC 受体激活和拮抗作用的结构动力学
  • 批准号:
    8214631
  • 财政年份:
    2010
  • 资助金额:
    $ 23.43万
  • 项目类别:
Structural dynamics underlying rho1 GABAC receptor activation and antagonism
rho1 GABAC 受体激活和拮抗作用的结构动力学
  • 批准号:
    7781716
  • 财政年份:
    2010
  • 资助金额:
    $ 23.43万
  • 项目类别:
Structural dynamics underlying rho1 GABAC receptor activation and antagonism
rho1 GABAC 受体激活和拮抗作用的结构动力学
  • 批准号:
    8053769
  • 财政年份:
    2010
  • 资助金额:
    $ 23.43万
  • 项目类别:
Structural dynamics underlying rho1 GABAC receptor activation and antagonism
rho1 GABAC 受体激活和拮抗作用的结构动力学
  • 批准号:
    8606217
  • 财政年份:
    2010
  • 资助金额:
    $ 23.43万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 23.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 23.43万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 23.43万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 23.43万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 23.43万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 23.43万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 23.43万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 23.43万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 23.43万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 23.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了